F Hoffmann-La Roche – Kinarus possesses worldwide rights to pamapimod in all therapeutic indications licensed from F. Hoffmann La Roche. Pamapimod is a highly-selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK) that has advanced through Phase 2 clinical development.

Ventac Partners – Kinarus collaborates with Ventac Partners, experts in business development, financing and partnering strategies in the biotechnology industry.